Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates

Core Insights - Lifeward Ltd. has entered into a distribution agreement with Verita Neuro to expand access to the ReWalk Personal Exoskeleton for spinal cord injury patients, targeting a total addressable market of approximately $1.75 billion [1][3] Group 1: Distribution Agreement - The agreement allows Verita Neuro to be the exclusive distributor of ReWalk in Mexico, Thailand, and the UAE, leveraging its established international presence [1][3] - Verita Neuro has a database of over 25,000 spinal cord injury patients and a network of rehabilitation centers, enhancing the reach of ReWalk [2] Group 2: Commercial Strategy - Lifeward's hybrid commercial model combines direct sales in the U.S. with third-party distribution in select international markets, aiming for increased sales volumes while managing operating expenses [3] - The partnership with Verita Neuro is intended to integrate ReWalk into their multi-modal treatment methodologies, which include surgical neural stimulation and stem cell therapy [3][4] Group 3: Rehabilitation Approach - Verita Neuro will implement a new delivery model that includes intensive in-patient training and rehabilitation for ReWalk, differing from the traditional outpatient training [4] - This approach is expected to enhance clinical adoption of ReWalk in various rehabilitation settings globally [4]